HealthyWay Inc. (2587) H2 2025 earnings summary

Executive summary

• Revenue rose ~30.1% YoY to RMB1,562.5m; net profit was RMB54.3m versus a 2024 net loss of RMB269.2m, which included a RMB272.8m redemption-liability charge.

• Corporate and digital marketing services drove expansion, while health and medical services revenue declined; gross margin remained 30.5%.

Financial highlights

• Revenue RMB1,562.5m, up from RMB1,200.8m; gross profit RMB476.3m, up from RMB365.9m; gross margin unchanged at 30.5%.

• Operating profit RMB62.1m versus RMB13.7m; profit before tax RMB59.3m versus a loss of RMB263.8m; net profit RMB54.3m versus a loss of RMB269.2m.

• Basic and diluted EPS RMB0.06 versus a loss per share of RMB0.38.

• Adjusted net profit was RMB22.8m in 2024; the non-IFRS measure was no longer considered necessary in 2025 after redemption rights ended on listing.

Outlook and guidance

• Strategy centers on scaling corporate services through pharmaceutical collaborations, real-world study data, regional joint ventures and a broader corporate-services ecosystem.

• Planned investment in AI Digital Employees aims to expand digital health interactions and corporate-services capacity; AI tools launched in 2025 and generated first-year direct sales.

• Digital marketing is expected to support cash flow; medical support services are targeted for steady, slightly increasing development, while pharmaceutical sales and healthcare packages will be scaled down.

• Management expressed optimism on business expansion and profitability, without providing quantified financial guidance.